Discovery DMPK: changing paradigms in the eighties, nineties and noughties

Bibliography

• Clarke SE, Jeffrey P. Utility of metabolic stability screening: comparison of in vitro and in vivo clearance. Xenobiotica 2001;31(8-9):591-8
   PubMed Web of Science ®Google Scholar
• Mohutsky MA, Chien JY, Ring BJ, Wrighton SA. Predictions of the in vivo clearance of drugs from rate of loss using human liver microsomes for phase I and phase II biotransformations. Pharm Res 2006;23(4):654-62
   PubMed Web of Science ®Google Scholar
• Hammarlund-Udenaes M. Friden M, Syvanen S, Gupta A: On the rate and extent of drug delivery to the brain. Pharm Res 2008;25(8):1737-50
   PubMed Web of Science ®Google Scholar
• Sui X, Sun J, Wu X, et al. Predicting the volume of distribution of drugs in humans. Curr Drug Metab 2008;9(6):574-80
   PubMed Web of Science ®Google Scholar
• Hutzler M, Messing DM, Wienkers LC. Predicting drug-drug interactions in drug discovery: where are we now and where are we going? Curr Opin Drug Discov Devel 2005;8(1):51-8
   PubMed Web of Science ®Google Scholar
• Martignoni M, Groothuis GM, De Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2006;2(6):875-94
   PubMed Web of Science ®Google Scholar
• Singh SS. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs. Curr Drug Metab 2006;7(2):165-82
   PubMed Web of Science ®Google Scholar
• Liu B, Chang J, Gordon WP, et al. Snapshot PK: a rapid rodent in vivo preclinical screening approach. Drug Discov Today 2008;13(7-8):360-7
   PubMed Web of Science ®Google Scholar
• Schmid EF, Smith DA. Keynote review: Is declining innovation in the pharmaceutical industry a myth? Drug Discov Today 2005;10(15):1031-9
   PubMed Web of Science ®Google Scholar
• Hanton G. Preclinical cardiac safety assessment of drugs. Drugs R D 2007;8(4):213-28
   PubMedGoogle Scholar
• Jalaie M, Holsworth DD. QT interval prolongation: and the beat goes on. Mini Rev Med Chem 2005;5(12):1083-91
   PubMed Web of Science ®Google Scholar
• Lawrence CL, Pollard CE, Hammond TG, Valentin JP. Nonclinical proarrhythmia models: predicting Torsades de Pointes. J Pharmacol Toxicol Methods 2005;52(1):46-59
   PubMedGoogle Scholar
• Zwillich T. How Vioxx is changing US drug regulation. The Lancet 2005;366(9499):1763-4
   PubMed Web of Science ®Google Scholar
• Brophy JM. Cardiovascular effects of cyclooxygenase-2 inhibitors. Curr Opin Gastroenterol 2007;23(6):617-24
   PubMed Web of Science ®Google Scholar
• Taylor D. Fewer drugs from the pharmaceutical industry. BMJ 2003;326(7386):408-9
   PubMed Web of Science ®Google Scholar
• Kola I. The State of Innovation in Drug Development. Clin Pharmacol Ther 2008;83(2):227-230
   PubMed Web of Science ®Google Scholar
• Food Drug. FDA Critical Path Initiatives white paper: innovation or stagnation? Challenge and opportunity on the critical path to new medical products. Available from: http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html. March 2004
   Google Scholar
• Pharma 2020: The Vision. Which path will you take? 2008 produced by PriceWaterHouse Coopers.
   Google Scholar
• Prentis RA, Walker SR. Trends in the development of new medicines by UK-owned pharmaceutical companies (1964-1980). Br J Clin Pharmacol 1986;21(4):437-43
   PubMed Web of Science ®Google Scholar
• Wardell WM. Hassar M, Anavekar SN, Lasagna L. The rate of development of new drugs in the United States, 1963 through 1975. Clin Pharmacol Ther 1978;24(2):133-45
   PubMed Web of Science ®Google Scholar
• Macinnes R, Lumley CE, Walker SR. New chemical entity output of the international pharmaceutical industry from 1970 to 1992. Clin Pharmacol Ther 1994;56(3):339-49
   PubMed Web of Science ®Google Scholar
• Covey TR, Crowther JB, Dewey EA, Henion JD. Thermospray liquid chromatography/mass spectrometry determination of drugs and their metabolites in biological fluids. Anal Chem 1985;57(2):474-81
   PubMed Web of Science ®Google Scholar
• Covey TR, Lee ED, Henion JD. High-speed liquid chromatography/tandem mass spectrometry for the determination of drugs in biological samples. Anal Chem 1986;58(12):2453-60
   PubMed Web of Science ®Google Scholar
• Stemp G. Chemistry strategies to reduce attrition in drug discovery. Chimica Oggi 2008;26(4):32-4
   Google Scholar
• Sun H, Chow EC, Liu S, et al. The Caco-2 cell monolayer: usefulness and limitations. Expert Opin Drug Metab Toxicol 2008;4(4):395-411
   PubMed Web of Science ®Google Scholar
• Mahar Doan KM, Humphreys JE, Webster LO, et al. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther 2002;303(3):1029-37
   PubMed Web of Science ®Google Scholar
• Manitpistkul P, White RE. Whatever happened to cassette-dosing pharmacokinetics? Drug Discov Today 2004;9(15):652-8
   PubMed Web of Science ®Google Scholar
• Leeson MP. Generation of a set of simple, interpretable ADMET rules of thumb. J Med Chem 2008;51(4):817-34
   PubMed Web of Science ®Google Scholar
• Tropsha A, Gramatica P, Gombar VK. The Importance of being earnest: validation is the absolute essential for Successful application and interpretation of QSPR models. QSAR Combin Sci 2003;22(1):69-77
   Google Scholar
• Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nature Rev Drug Discov 2004;3:711-5
   PubMed Web of Science ®Google Scholar
• Pelkonen O, Kapitulnik J, Gundert-Remy U, et al. Local kinetics and dynamics of xenobiotics. Critical Rev Toxicol 2008;38:697-720
   PubMed Web of Science ®Google Scholar
• Riemann B, Schafers KP, Schober O, Schafers M. Small animal PET in preclinical studies: opportunities and challenges. Q J Nucl Med Mol Imaging 2008;52(3):215-21
   PubMed Web of Science ®Google Scholar
• Beckmann N, Knuer R, Gremlich HU, Karmouty-Quintana H, Bié FX, Müller M. In vivo mouse imaging and spectroscopy in drug discovery. NMR Biomed 2007;20(3):154-85
   PubMed Web of Science ®Google Scholar
• Upton RN. Cerebral uptake of drugs in humans. Clin Exp Pharmacol Physiol 2007;34(8):695-701
   PubMed Web of Science ®Google Scholar
• De Lange EC, Ravenstijn PG, Groenendaal D, Van Steeg TJ. Toward the prediction of CNS drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic-pharmacodynamic modeling. AAPS J 2005;7(3):E532-43
   PubMed Web of Science ®Google Scholar
• Jeffrey P, Summerfield SG. Blood-brain barrier screening. Xenobiotica 2007;37(10):1135-51
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23:3-25
   Web of Science ®Google Scholar
• Didziapetris R, Japertas P, Avdeef A, Petrauskas A. Classification Analysis of P-Glycoprotein Substrate Specificity. J Drug Target 2003;11(7):391-406
   PubMed Web of Science ®Google Scholar
• van De Waterbeemd H, Smith DA, Jones BC. Lipophilicity in PK design: methyl, ethyl, futile. J Comput Aided Mol Des 2001;15(3):273-86
   PubMed Web of Science ®Google Scholar
• Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nature Rev Drug Discov 2007;6:881-90
   PubMed Web of Science ®Google Scholar
• Hughes JD, Blagg J, Price DA, et al. Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg Med Chem Lett 2008;18(17):4872-5
   PubMed Web of Science ®Google Scholar
• Summerfield SG, Jeffrey P. In vitro prediction of brain penetration: a case for free thinking? Exp Opin Drug Discov 2006;1(6):595-607
   PubMed Web of Science ®Google Scholar
• Mahmood I. Application of allometric principles for the prediction of pharmacokinetics in human and veterinary drug development. Adv Drug Deliv Rev 2007;59(11):1177-92
   PubMed Web of Science ®Google Scholar
• Theil FP, Guentert TW, Haddad S, Poulin P. Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. Toxicol Lett 2003;138(1-2):29-49
   PubMed Web of Science ®Google Scholar
• Rostami-Hodjegan A, Tucker GT. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 2007a;2:140-48
   Web of Science ®Google Scholar
• Lovich MA, Edelman ER. Tissue concentration of heparin, not administered dose, correlates with the biological response of injured arteries in vivo. Proc Nat Acad Sci 1999;96(20):11111-6
   PubMed Web of Science ®Google Scholar
• Ozawa CR, Banfi A, Glazer NL, et al. Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J Clin Invest 2004;113(4):516-27
   PubMed Web of Science ®Google Scholar
• Zhou SF. Potential strategies for minimizing mechanism-based inhibition of cytochrome P450 3A4. Curr Pharm Des 2008;14(10):990-1000
   PubMed Web of Science ®Google Scholar
• Strange K. The end of “naive reductionism”: rise of systems biology or renaissance of physiology? Am J Physiol Cell Physiol 2005;288(5):C968-74
   PubMed Web of Science ®Google Scholar
• Wolkenhauer O. Systems biology: The reincarnation of systems theory applied in biology? Systems biology: the reincarnation of systems theory applied in biology? Brief Bioinform 2001;2(3):258-70
   PubMedGoogle Scholar
• Ge H, Walhout AJ, Vidal M. Integrating ‘omic’ information: a bridge between genomics and systems biology. Trends Genet 2003;19(10):551-60
   PubMed Web of Science ®Google Scholar
• Thomas CE, Ganji G. Integration of genomic and metabonomic data in systems biology–are we ‘there’ yet? Curr Opin Drug Discov Devel 2006 ;9(1):92-100
   PubMed Web of Science ®Google Scholar
• Tomita M, Hashimoto K, Takahashi K, et al. E-CELL: Software Environment for Whole Cell Simulation. Genome Inform Ser Workshop Genome Inform 1997;8:147-55
   PubMedGoogle Scholar
• Csajka C, Verotta D. Pharmacokinetic-pharmacodynamic modelling: history and perspectives. J Pharmacokinet Pharmacodyn 2006;33(3):227-79
   PubMed Web of Science ®Google Scholar
• Della Paschoa OE, Kruk MR, Danhof M. Phamacokinetic-pharmacodynamic modelling of behavioural responses. Neurosci Biobehav Rev 1998;23(2):229-36
   PubMed Web of Science ®Google Scholar
• Zuideveld KP, Van Der Graff PH, Newgreen D, et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling of 5-HT1A receptor agonists: estimation of in vivo affinity and intrinsic efficacy on body temperature in rats. J Pharmacol Exp Ther 2004;308:1012-20
   PubMed Web of Science ®Google Scholar
• Edginton AN, Theil FP, Schmitt W, Willmann S. Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opin Drug Metab Toxicol 2008;4(9):1143-52
   PubMed Web of Science ®Google Scholar
• Liu X, Smith BJ, Chen C, et al. Use of a physiologically based pharmacokinetics model to study the time to reach brain equilibrium: an experimental analysis if the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding. J Pharmacol Exp Ther 2006;313:1254-62
   Web of Science ®Google Scholar
• Lavé T, Parrot N, Grimm HP, et al. Challenges and opportunities with modelling and simulation in drug discovery and drug development. Xenobiotica 2007;37(10-11):1295-310
   PubMed Web of Science ®Google Scholar
• Schmitt W, Willman S. Physilogically-based pharmacokinetic modelling: ready to be used. Drug Discov Today 2005;2(1):125-32
   Google Scholar
• Ekins S, Bugrim A, Brovold L, et al. Algorithms for network analysis in systems-ADME/Tox using the MetaCore and MetaDrug platforms. Xenobiotica 2006;36(10-11):877-901
   PubMed Web of Science ®Google Scholar
• Zhang H, Hu S, Zhang Y. Prediction of distribution of neutral, acidic and basic structurally diverse compounds between blood and brain by the nonlinear methodology. Med Chem 2008;2:170-89
   Web of Science ®Google Scholar
• Platts JA, Abraham MH, Zhao YH, et al. Correlation and prediction of a large blood-brain distribution data set-an LFER study. Eur J Med Chem 2001;36(9):719-30
   PubMed Web of Science ®Google Scholar
• Hou T, Wang J, Zhang W, Xu X. ADME evaluation in drug discovery. 7. Prediction of oral absorption by correlation and classification. J Chem Inf Model 2007;47(1):208-18
   PubMed Web of Science ®Google Scholar
• Yoshida F, Topliss JG. QSAR model for drug human oral bioavailability. J Med Chem 2000;43(13):2575-85. Erratum in: J Med Chem 2000;30,43(24):4723
   PubMed Web of Science ®Google Scholar
• Cronin MTD, Schultz TW. Pitfalls in QSAR. J Mol Struct 2003;622(1-2):39-51
   Web of Science ®Google Scholar
• Schrattenholz A, Soski V. What does systems biology mean for drug development? Curr Med Chem 2008;15(15):1520-8
   PubMed Web of Science ®Google Scholar
• Fischer HP. Towards quantitative biology: integration of biological information to elucidate disease pathways and to guide drug discovery. Biotechnol Annu Rev 2005;11:1-68
   PubMedGoogle Scholar
• Liao G, Zhang X, Clark DJ, Peltz G. A genomic “roadmap” to “better” drugs. Drug Metab Rev 2008;40(2):225-39
   PubMed Web of Science ®Google Scholar
• Hines RN. The ontengy of drug metabolising enzymes and implications for adverse drug reactions. Pharmacol Ther 2008;118:250-67
   PubMed Web of Science ®Google Scholar
• Zhang MQ, Wilkinson B. Drug discovery beyond the ‘rule-of-five’. Curr Opin Biotechnol 2007;18(6):478-88
   PubMed Web of Science ®Google Scholar
• Quote from Patrick Vallance, current senior vice president of drug discovery GlaxoSmithKline R&D.
   Google Scholar
• Meibohm B, Derendorf H. Pharmacokinetic/pharmacodynamic studies in drug product development. J Pharm Sci 2002;91(1):18-31
   PubMed Web of Science ®Google Scholar
• Camenisch G, Alsenz J, Van De Waterbeemd H, Folkers G. Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight. Eur J Pharm Sci 1998;6(4):317-24
   PubMed Web of Science ®Google Scholar
• Summerfield SG, Read K, Begley DJ, et al. Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction. J Pharmacol Exp Ther 2007;322(1):205-13
   PubMed Web of Science ®Google Scholar
• Crivori P, Reinach B, Pezzetta D, Poggesi I. Computational models for identifying potential P-glycoprotein substrates and inhibitors. Mol Pharm 2006;3(1):33-44
   PubMed Web of Science ®Google Scholar
• Riley RJ, Parker AJ, Trigg S, Manners CN. Development of a generalized, quantitative physicochemical model of CYP3A4 inhibition for use in early drug discovery. Pharm Res 2001;18(5):652-5
   PubMed Web of Science ®Google Scholar
• Gleeson MP, Davis AM, Chohan KK, et al. Generation of in-silico cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A4 inhibition QSAR models. J Comput Aided Mol Des 2007;21(10-11):559-73
   PubMed Web of Science ®Google Scholar
• Summerfield SG, Stevens AJ, Cutler L, et al. Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain. J Pharmacol Exp Ther 2006;316(3):1282-90
   PubMed Web of Science ®Google Scholar
• Jansson R, Bredberg U, Ashton M. Prediction of drug tissue to plasma concentration ratios using a measured volume of distribution in combination with lipophilicity. J Pharm Sci 2008;97(6):2324-39
   PubMed Web of Science ®Google Scholar
• Smith DA, Van de Waterbeemd H, Walker DK, editors. Pharmacokinetics and metabolism in drug design: chapter 4 distribution. Wiley-VCH Verlag GmbH; 2001. p.47-57
   Google Scholar
• Gibson G, Rostami-Hodjegan A, editors: Modelling and simulation approaches to in vitro-in vivo extrapolation of ADME properties in drug development. Xenobiotica Special Issue. 2007;37(10/11)
   Google Scholar
• Katz DA, Murray B, Bhathena A, Sahelijo L. Defining drug disposition determinants: a pharmacogenetic-pharmacokinetic strategy. Nat Rev Drug Discov 2008;7:293-305
   PubMed Web of Science ®Google Scholar